Pfizer has released initial data from its obesity drug pipeline, which was acquired through the $10 billion purchase of Metsera last fall. According to BMO Capital Markets, the data "look competitive," but analysts on Pfizer’s earnings call sought further details and did not receive additional information.
Merck addressed analyst concerns about its growth during its own earnings call. CEO Robert Davis stated, “probably the broadest and widest pipeline we’ve had in years,” while dismissing claims of only modest progress.
These updates come as several major pharmaceutical companies report their financial results. Roche and Johnson & Johnson have already presented their earnings, with Eli Lilly, Novo Nordisk, Novartis, AbbVie, and others scheduled to follow.
The U.S. Food and Drug Administration (FDA) is expected to make decisions on eight products this month. Among them is REGENXBIO’s Hunter syndrome gene therapy RGX-121. Last week, the FDA placed a clinical hold on two REGENXBIO programs, including RGX-121. The agency also launched the PreCheck pilot program to streamline construction of manufacturing facilities in the United States. President Donald Trump’s TrumpRx platform has been delayed, possibly due to anti-kickback concerns.
In coverage of emerging therapies, attention has turned to psychedelics research. Two companies—Compass Pathways and Definium—may submit FDA applications for psychedelic-based treatments this year. H.C. Wainwright analyst Patrick Trucchio told BioSpace that 2026 could be “the biggest year from a clinical data standpoint,” since his firm began tracking Compass Pathways in 2018.
BioPharm Executive will provide an update Wednesday reviewing biotechnology companies that went public during 2021.
